Used in the treatment of various solid tumors, particularly in advanced or metastatic cancers such as pancreatic, ovarian, and non-small cell lung cancer. It functions as a prodrug of gemcitabine, designed to overcome resistance mechanisms that limit the effectiveness of gemcitabine in some patients. By improving cellular uptake and retention, it enhances cytotoxic activity against tumor cells. It is under clinical investigation for its potential to provide better therapeutic outcomes in patients who have failed prior gemcitabine-based therapies. Its application is primarily in oncology, especially in settings where conventional nucleoside analogs show limited efficacy.